Skip to main content

Table 4 Association between extubation in the OR and composite mechanical ventilation-related adverse outcomesa

From: Extubation in the operating room results in fewer composite mechanical ventilation-related adverse outcomes in patients after liver transplantation: a retrospective cohort study

Characteristics

All recipients Univariable P valve

Multivariable analysis Odds Ratio (95%CI)

P valve

Matched recipients Univariable P valve

Multivariable analysis Odds Ratio (95%CI)

P valve

Sex

0.029

—

—

0.68

—

—

ASA-classification (n), %

<0.001

0.488 (0.163~1.461)

0.200

0.051

0.640 (0.163~2.513)

0.523

Renal dysfunction (eGFR <60ml/min/1.73m2)

0.091

2.161 (0.927~5.037)

0.074

>0.999

0.680 (0.139~3.316)

0.633

MELD score

0.003

0.999 (0.966~1.033)

0.963

0.713

1.022 (0.987~1.058)

0.228

Preoperative artificial liver support

0.094

1.129 (0.515~2.474)

0.763

0.977

3.645 (0.680~19.535)

0.131

Basic SpO2

0.079

0.858 (0.769~0.957)

0.006

0.119

0.844 (0.720~0.990)

0.037

Preoperative-Hemoglobin (g/L)

0.015

—

—

0.940

—

—

PT (s)

0.001

—

—

0.600

—

—

APTT (s)

0.013

—

—

0.691

—

—

INR

0.001

—

—

0.497

—

—

Total bilirubin (μmol/L)

0.009

—

—

0.725

—

—

Albumin (g/L)

<0.001

—

—

0.299

—

—

Duration of surgery (h)

<0.001

1.091 (0.963~1.235)

0.171

0.629

1.054 (0.857~1.296)

0.617

Urine output

0.026

—

—

0.643

—

—

Packed red blood cell transfusion (U)

<0.001

1.083 (1.052~1.115)

<0.001

0.155

1.085 (1.025~1.148)

0.005

Maximal vasopressors need (μg/kg/min)

<0.001

—

—

0.298

—

—

Maximal lactate (mmol/L)

<0.001

1.041 (0.992~1.092

0.102

0.930

1.069 (0.996~1.146)

0.064

Extubation

—

0.518 (0.290~0.924)

0.026

—

0.514 (0.270~0.981)

0.044

  1. ASA American Society of Anesthesiologists, MELD Model for End-Stage Liver Disease, SpO2 Oxygen saturation, PT Prothrombin time, APTT Activated partial thromboplastin time, INR International normalized ratio, CI Confidence Index
  2. aComposite mechanical ventilation-related adverse outcomes includes 30-day all-cause mortality, in-hospital acute kidney injury (stage 2 or 3), or in-hospital moderate to severe pulmonary complications.